To understand key trends
Download Free Sample
Based on product type, the non-animal alternative testing market is segmented into organs-on-chips, cell lines, and tissue lines. The organ-on-chips segment dominated in 2022 with a market size of USD 872.9 million. The advantages of organ-on-chips (OOCs) over cell culture, animal models, and human clinical trials have attracted the interest of both the medical and pharmaceutical communities, that are working on producing personalised medicines.
For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) established a novel concept for Organs-on-a-Chip to investigate treatments for inflammatory diseases and ailments. Organs-on-a-chip are made up of millions of cells arranged on a platform to mimic the functioning of various organs and can be used as a tool for assessing and developing new treatments for complicated diseases without the usage of animals. Such benefits offered by OOCs is expected to propel the segmental growth.
To understand key market trends
Download Free Sample
Based on technology, the non-animal alternative testing market is segmented into cell culture technology, high throughput technology, molecular imaging, and omics technology. The cell culture technology segment accounted for USD 746.9 million in 2022. The increase is due to the fact that researchers frequently utilise cell culture technologies for analysing a large number of test results at once. Also, numerous pharmacological experiments are performed on eukaryotic cells, preferably human cells, that have been cultured under strictly monitored in vitro conditions to mimic the external environment of the human body.
Based on application, the non-animal alternative testing market is segmented into infectious diseases, immunological diseases, oncology, cardiovascular diseases, diabetes, genetic diseases, and neurological diseases. The infectious diseases segment dominated the market in 2022, with a CAGR of 7.8%. The dominance of segment is due to the fact that scientists estimate that more than 6 out of every 10 known infectious diseases in people can be spread from animals, and 3 out of every 4 new or emerging infectious diseases in people come from animals. Hence, the utilization of non-animal alternative testing for infectious diseases will accelerate the market growth.
Based on end-user, the non-animal alternative testing market is segmented into pharmaceutical companies, biotechnological companies, the cosmetics industry, research institutes & academics, contract research organization (CROs) and other end-users. The pharmaceutical industry segment is expected show 11% CAGR during the analysis period. The expansion is due to the pharmaceutical sector boosting its research and development efforts to provide new treatments for a variety of conditions. Also, rising disapproval to using animals for drug testing is further inspiring corporations to use in silico drug testing procedures to avoid any type of ethics concern. As a result, the market for non-animal alternative testing is predicted to increase at an exponential rate in the forecast period.
To understand regional trends  Download Free Sample
North America non-animal alternative testing market surpassed USD 653.8 million in 2022 with a growth rate of 8.2%. The region is dominating due to the presence of key players in these regions along with rising government support for non-animal alternative testing. Also, increasing prevalence of chronic diseases along with investment by key players in R&D activities to develop novel product is expected to supplement the market landscape.